摘要
目的观察吡拉西坦注射液联合胞磷胆碱注射液治疗缺血性脑卒中的临床疗效与安全性。方法将94例缺血性脑卒中患者随机分为对照组47例和试验组47例。对照组予以吡拉西坦每次20 g,qd,静脉注射;试验组在对照组治疗的基础上,予以胞磷胆碱每次0.5 g,qd,静脉滴注。2组患者均治疗14 d。比较2组患者的临床疗效、血清单核细胞趋化蛋白-1(MCP-1)、同型半胱氨酸(HCY)、高密度脂蛋白胆固醇(HDL-C)水平,以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为87.23%(41例/47例)和63.83%(30例/47例),差异有统计学意义(P<0.05)。治疗后,试验组和对照组的血清MCP-1分别为(90.74±10.33)和(120.71±15.42)pg·mL^(-1),HCY分别为(16.68±2.24)和(21.01±3.03)μmol·L^(-1),HDL-C分别为(1.31±0.16)和(1.12±0.13)mmol·L^(-1),差异均有统计学意义(均P<0.05)。试验组发生的药物不良反应以失眠、食欲缺乏和口干为主,对照组发生的药物不良反应以皮疹、腹泻和低血压为主。试验组和对照组的总药物不良反应发生率分别为10.64%和14.89%,差异无统计学意义(P>0.05)。结论吡拉西坦注射液联合胞磷胆碱注射液治疗缺血性脑卒中的临床疗效确切,其能显著降低患者的血清MCP-1及HCY水平,升高HDL-C水平,且不增加药物不良反应的发生率。
Objective To observe the clinical efficacy and safety of priacetam injection combined with citicoline injection in the treatment of ischemic stroke. Methods Ninety-four patients with ischemic stroke were randomly divided into control group and treatment group with 47 cases per group. Control group was given piracetam 20 g per time,qd,intravenous injection. Treatment group was given citicoline 0. 5 g per time,qd,intravenous injection,on the basis of the control group. Two groups were treated for 14 days. The clinical efficacy,serum monocyte chemoattractant protein-1（ MCP-1）,homocysteine（ HCY）,high density lipoprotein cholesterol（ HDL-C）,and adverse drug reactions were compared between two groups. Results After treatment,the total effective rates in treatment and control groups were 87. 23%（ 41 cases/47 cases） and 63. 83%（ 30 cases/47 cases） with significant difference（ P 〈0. 05）. After treatment,the main indexes in treatment and controlgroups were compared： serum MCP-1 were（ 90. 74 ± 10. 33） and（ 120. 71 ± 15. 42） pg·mL^（-1）,HCY were（ 16. 68 ± 2. 24） and（ 21. 01 ± 3. 03） μmol·L^（-1）,HDL-C were（ 1. 31 ± 0. 16） and（ 1. 12 ± 0. 13） mmol·L^（-1）,the differences were statistically significant（ all P〈 0. 05）. The adverse drug reactions in treatment group were insomnia,lack of appetite and dry mouth,which in control group were rash,diarrhea and hypotension. The incidences of adverse drug reactions in treatment and control groups were 10. 64% and 14. 89% without significant difference（ P〉 0. 05）. Conclusion Priacetam injection combined with citicoline injection has a definitive clinical efficacy in the treatment of ischemic stroke,which can significantly reduce the levels of serum MCP-1 and HCY,improve the levels of HDL-C,without increasing the incidence of adverse drug reactions.
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2018年第3期200-202,共3页
The Chinese Journal of Clinical Pharmacology
基金
浙江省医药卫生科技计划基金资助项目(2012KYB243)
浙江省中医药科学研究基金资助项目(2015ZA132)
